SEMA3C Supports Pancreatic Cancer Progression by Regulating the Autophagy Process and Tumor Immune Microenvironment

To date, driver genes for pancreatic cancer treatment are difficult to pursue therapeutically. Targeting mutated KRAS, the most renowned driver gene in pancreatic cancer, is an active area of study. We discovered a gene named SEMA3C was highly expressed in pancreatic cancer cell lines and patients w...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Dalin, Lindstrom, Aaron, Kim, Edward J, Hwang, Chang-il, Hall, Madison Lee, Lin, Tzu-Yin, Li, Yuanpei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9243227/
https://www.ncbi.nlm.nih.gov/pubmed/35785187
http://dx.doi.org/10.3389/fonc.2022.890154

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9243227/
https://www.ncbi.nlm.nih.gov/pubmed/35785187
http://dx.doi.org/10.3389/fonc.2022.890154

Ejemplares similares